European Archives - Page 513 of 1164 - European Medical Journal

EMJ Hepatology 10.1 Feature Image

Review of the European Association for the Study of Liver (EASL) International Liver Congress (ILC) 2022 Congress

AFTER a 3-year wait to meet in-person since the 2019 congress in Vienna, Austria, the European Association for the Study of Liver (EASL) International Liver Congress (ILC) took place in London, UK, from 22nd–26th June 2022. This year marked the 57th anniversary of the annual ILC event, and welcomed over 5,300 delegates on site, and over 1,300 virtually from 112 countries.

EMJ Hepatology 10.1 Feature Image

Holistic Patient Care in Primary Biliary Cholangitis

PBC is an immune-mediated, chronic, progressive liver disease characterised by gradual destruction of intrahepatic bile ducts.

EMJ Hepatology 10.1 Feature Image

Prescription Event Monitoring of Checkpoint Inhibitor-Induced Liver Injury and Outcomes of Rechallenge: A 10-Year Experience

The definition and severity of checkpoint inhibitor-induced liver injury (ChILI) have been reported using the Common Terminology Criteria for Adverse Events (CTCAE) used in cancer therapy.

Paediatric Acute-on-Chronic Liver Failure

There is growing recognition of acute-on-chronic liver failure (ACLF) as a distinct clinical syndrome that portends excessively high…

EMJ Hepatology 10.1 Feature Image

Critical Care Management of Acute Decompensation of Cirrhosis

ON DAY 2 of the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022, which took place on 22nd–26th June 2022 in London, UK, there was a session featuring specialist insights from researchers in the field. There were discussions that focused on the critical management of acute decompensation of cirrhosis.

EMJ Hepatology 10.1 Feature Image

Management of Severe, Steroid-Resistant and Steroid-Refractory Hepatotoxicity in Patients Treated with Checkpoint Inhibitor Immunotherapy

Checkpoint inhibitor immunotherapy (ICI) has revolutionised cancer care but is associated with immune-related toxicities, which may require ICI discontinuation and immunosuppressive therapies (IST).

EMJ Hepatology 10.1 Feature Image

Pre-transplant Changes in Serum Protein Glycosylation Relates to Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation and Provide a Potential Prognostic Biomarker: A Proof-of-Concept Study

Hepatocellular carcinoma (HCC) recurs after liver transplantation (LT) in approximately 10% of patients. Changes in protein glycosylation have been described during the development of HCC and are associated with progressive disease and early mortality.

Congress Interview - Aleksander Krag

EASL 2022 Congress Interview: Aleksander Krag

Hepatology is an exciting and challenging clinical discipline with many great research opportunities and a vibrant international community.

EMJ Hepatology 10.1 Feature Image

Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences

Non-alcoholic steatohepatitis (NASH) is the potentially progressive form of non-alcoholic fatty liver disease (NAFLD). NAFLD and NASH are very common in most regions of the world and are on trajectory to become the most common liver disease at a global scale. Risk for high prevalence and progressiveness include visceral obesity and Type 2 diabetes.

Post-traumatic Isolated Right Hepatic Duct Injury: A Case Report

A 73-year-old female presented with a rare presentation of extrahepatic ductal injuries post-trauma in the form of a right hepatic duct injury. Such injuries go undetected despite normally advised imaging, presenting a few to several days post-trauma.